Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025
14/10 12:23
Company Announcement Net sales of DARZALEX ® in the third quarter of 2025 totaled USD 3,672 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (Nasdaq: GMAB) announced today...